Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial

Published:2017-03-17 Issue:3 Volume:18 Page:135-140
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Post Frank A.¹,Yazdanpanah Yazdan²,Schembri Gabriel³,Lazzarin Adriano⁴,Reynes Jacques⁵,Maggiolo Franco⁶,Yan Mingjin⁷,Abram Michael E.⁷^ORCID,Tran-Muchowski Cecilia⁷,Cheng Andrew⁷,Rhee Martin S.⁷

Affiliation:

1. Kings College Hospital NHS Foundation Trust, Weston Education Centre (2.53), London, UK

2. Service des Maladies Infectieuses et Tropicales, Hospital Bichat-Claude Bernard, Paris, France

3. Manchester Centre for Sexual Health, Manchester, UK

4. Divisione di Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy

5. Departement Des Maladies Infectieuses et Tropicales, CHU Gui De Chuliac, Montpellier, France

6. US di Terapia Antivirale, USC di Malattie Infettive, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

7. Departments of Biometrics, Virology, Clinical Operations, and Clinical Research, Gilead Sciences Inc., Foster City, CA, USA

Funder

Gilead Sciences

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/15284336.2017.1291867

Reference17 articles.

1. Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence

2. Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System

3. Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges;Microorganisms;2022-02-14

2. Implications of weight gain with newer antiretrovirals;AIDS;2021-04-28

3. Raman-based metabonomics unravels metabolic changes related to a first-line tenofovir-based treatment in a small cohort of South African HIV-infected patients;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2021-03

4. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group;International Journal of STD & AIDS;2021-02-20

5. Fractures in children and adolescents living with perinatally acquired HIV;Bone;2020-10